Skip to main content

Celgene Corp (CELG-Q) Quote

Unchecking box will stop auto data updates
Cboe BZX Real-Time Last Sale USD
Today's Change
Volume
Price Quote as of

Today's Trading

Day Low 109.52
Day High 110.53
Open:109.95
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

More stories below advertisement

Description
Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Their portfolio of commercial products include REVLIMID, VIDAZA, THALOMID, POMALYST/IMNOVID, ABRAXANE, OTEZLA, ISTODAX and IDHIFA. The drug candidates in their pipeline are at various stages of preclinical and clinical development. These candidates include their IMiDs compounds, which are a proprietary class of compounds that have certain immunomodulatory and other biologically important properties in addition to their leading oral anti-inflammatory agents and cellular therapies. They believe their commercial stage products and the depth of their product pipeline, provide the catalysts for future growth.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Zacks Investment Research, including Income Statements, Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.

Stock Reports +

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

StockCalc Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

ValuEngine Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Latest Press Releases

Celgene Corp Rises 9.25% on Heavy Volume: Watch For Potential Pullback
- Comtex SmarTrend(R) - Tue Nov 12, 11:21AM CST
Comtex SmarTrend(R) - CMTX
Tue Nov 12, 11:21AM CST
Celgene Corp (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $109.40 to a high of $109.78. Yesterday, the shares gained 9.3%, which took the trading range above the 3-day high of $109.75 on volume of 202,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Skyhawk Therapeutics Announces a Second Multi-Target Collaboration Agreement with Celgene to Discover and Develop Novel Small Molecules that Modulate RNA Splicing
- PR Newswire - Tue Nov 12, 8:00AM CST
PR Newswire - CMTX
Tue Nov 12, 8:00AM CST
Celgene to receive exclusive options to license a number of Skyhawk's product candidates directed to multiple high-value autoimmune disorder, oncology, and immuno-oncology targets.
Skyhawk Therapeutics Announces a Second Multi-Target Collaboration Agreement with Celgene to Discover and Develop Novel Small Molecules that Modulate RNA Splicing
- PR Newswire - Tue Nov 12, 8:00AM CST
PR Newswire - PRNW
Tue Nov 12, 8:00AM CST
Celgene to receive exclusive options to license a number of Skyhawk's product candidates directed to multiple high-value autoimmune disorder, oncology, and immuno-oncology targets. 
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 100.40 +9.58% increase
on 10/15/19
Period Open:100.39
Price movement based on the high, low and last over the given period.
110.70 -0.61% decrease
on 11/13/19
+9.63 (+9.59%) increase
since 10/14/19
3-Month 92.70 +18.68% increase
on 08/15/19
Period Open:92.89
Price movement based on the high, low and last over the given period.
110.70 -0.61% decrease
on 11/13/19
+17.13 (+18.44%) increase
since 08/14/19
52-Week 58.59 +87.78% increase
on 12/26/18
Period Open:69.63
Price movement based on the high, low and last over the given period.
110.70 -0.61% decrease
on 11/13/19
+40.39 (+58.01%) increase
since 11/14/18

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2019.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).